OROPHARYNGEAL
HPV PCR TESTING—PATENT PENDING
FOR DENTISTS & HEALTHCARE PROVIDERS
Revolutionary
“Dentists and Dental Hygienists possess unparalleled access to patients' throats.”
- Dr. Mohammad Kamal
HPV-related squamous cell carcinoma of the oropharynx is one of the fastest growing cancers.
OmniPathology's proprietary, patent pending oropharyngeal HPV test offers a practical and cost-effective way to screen for this HPV-related cancer. With 95% sensitivity and 100% specificity, Omni presents its laboratory developed (LDT) qualitative real time PCR test that detects 14 high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Specimen collection is as easy as obtaining an oropharyngeal (throat) swab and placing it in viral collection media.
IT’S ABOUT CANCER PREVENTION…
HOW TO COLLECT THE SAMPLE
-
Squamous cell carcinoma originates from epithelial cells lining the oral and oropharyngeal mucosa.
In the head and neck region, HPV16 represents the primary viral cause of squamous cell cancers.
Persistent HPV infection is linked to increased risk of developing cancer.
The lack of effective screening results in nearly all patients with oropharyngeal cancers presenting with advanced tumors.
The mortality rate is 50%.
-
8th leading cause of cancer worldwide
6th squamous cell carcinoma is the common malignancy
>90% of all oral malignancies are squamous cell carcinoma
About 54,540 new cases of oral cavity or oropharyngeal cancer (USA)
About 11,580 deaths from oral cavity or oropharyngeal cancer (USA)
Learn about OmniOP2 and the future of HPV Prevention
